Global Talazoparib Market
Global Talazoparib Market

Talazoparib Comprehensive Study by Type (0.25mg Capsules, 1mg Capsules), Application (Hospital, Drug Center, Clinic), Disease Type (Treat Prostate Cancer, Breast Cancers, Endometrial Cancer, Uterine Cancer, Other), Distribution Channel (Online, Offline, Specialty Stores, Pharmacy Shops) Players and Region - Global Market Outlook to 2025

Talazoparib Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jul 2020 Edition 242 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Talazoparib Market Overview:
Talazoparib, sold under the brand name Talzenna, is an orally available inhibitor of the poly-ADP-ribose polymerase (PARP) developed by Pfizer to treat advanced breast cancer with BRCA mutations in the germline. Talazoparib is similar to the first PARP inhibitor in its class, olaparib. It was approved in October 2018 in the United States and in June 2019 in the European Union for BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer in the germline. The most serious side effects in studies concerned the hematopoietic system and included anemia (low red blood cell count), neutropenia (low neutrophil count) and thrombocytopenia (low platelet count). Serious forms of these diseases (grade 3 to 4) occurred in 39%, 21%, and 15% of the patients. Other side effects such as headache, nausea, hair loss, and fatigue were mostly mild. Talazoparib acts as an inhibitor of poly-ADP ribose polymerase (PARP), which aids in the repair of single-stranded DNA. Cells with BRCA1 / 2 mutations are susceptible to the cytotoxic effects of PARP inhibitors due to the accumulation of DNA damage. Talazoparib is believed to be more potent than olaparib due to the additional mechanism of action known as PARP trapping. PARP trapping is the mechanism of action in which the PARP molecule is trapped on the DNA, which impairs the ability of the cell to replicate. Talazoparib is ~ 100 times more efficient than olaparib in trapping PARP. However, this increased efficacy may not lead directly to clinical efficacy as many other factors need to be considered. Some of the players profiled in the study are Pfizer (United States).

On the basis of geography, the market of Talazoparib has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Treat Prostate Cancer will boost the Talazoparib market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Talazoparib market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Growing Geriatric Population in Major Economies
  • Increasing No of Cancer Patients Worldwide
  • Growing Usage because of its Cost-Effectiveness as Compare to Chemo Therapy

Influencing Trend
  • Increasing Healthcare Spending and Demand for Drug Therapy

Restraints
  • Stringent Government Rules and Regulation
  • Side Effects Due to Talazoparib Drug

Opportunities
  • R&D and Product Innovation
  • Potential Growth From Emerging Countries

Challenges
  • Availability of Substitutes




The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.

Target Audience:
Manufacturers of Talazoparib, Suppliers and Distributors of Talazoparib, Raw Material Suppliers, Commercial Research & Development (R&D) Institutions, Government Organizations, Research Organizations and Healthcare Industry

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Talazoparib market on the basis of product [0.25mg Capsules and 1mg Capsules] , application [Hospital, Drug Center and Clinic], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Talazoparib market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Talazoparib industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Talazoparib market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • 0.25mg Capsules
  • 1mg Capsules
By Application
  • Hospital
  • Drug Center
  • Clinic
By Disease Type
  • Treat Prostate Cancer
  • Breast Cancers
  • Endometrial Cancer
  • Uterine Cancer
  • Other

By Distribution Channel
  • Online
  • Offline
  • Specialty Stores
  • Pharmacy Shops

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population in Major Economies
      • 3.2.2. Increasing No of Cancer Patients Worldwide
      • 3.2.3. Growing Usage because of its Cost-Effectiveness as Compare to Chemo Therapy
    • 3.3. Market Challenges
      • 3.3.1. Availability of Substitutes
    • 3.4. Market Trends
      • 3.4.1. Increasing Healthcare Spending and Demand for Drug Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Talazoparib, by Type, Application, Disease Type, Distribution Channel and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Talazoparib (Value)
      • 5.2.1. Global Talazoparib by: Type (Value)
        • 5.2.1.1. 0.25mg Capsules
        • 5.2.1.2. 1mg Capsules
      • 5.2.2. Global Talazoparib by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Drug Center
        • 5.2.2.3. Clinic
      • 5.2.3. Global Talazoparib by: Disease Type (Value)
        • 5.2.3.1. Treat Prostate Cancer
        • 5.2.3.2. Breast Cancers
        • 5.2.3.3. Endometrial Cancer
        • 5.2.3.4. Uterine Cancer
        • 5.2.3.5. Other
      • 5.2.4. Global Talazoparib by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
        • 5.2.4.3. Specialty Stores
        • 5.2.4.4. Pharmacy Shops
      • 5.2.5. Global Talazoparib Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Talazoparib (Volume)
      • 5.3.1. Global Talazoparib by: Type (Volume)
        • 5.3.1.1. 0.25mg Capsules
        • 5.3.1.2. 1mg Capsules
      • 5.3.2. Global Talazoparib by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Drug Center
        • 5.3.2.3. Clinic
      • 5.3.3. Global Talazoparib by: Disease Type (Volume)
        • 5.3.3.1. Treat Prostate Cancer
        • 5.3.3.2. Breast Cancers
        • 5.3.3.3. Endometrial Cancer
        • 5.3.3.4. Uterine Cancer
        • 5.3.3.5. Other
      • 5.3.4. Global Talazoparib by: Distribution Channel (Volume)
        • 5.3.4.1. Online
        • 5.3.4.2. Offline
        • 5.3.4.3. Specialty Stores
        • 5.3.4.4. Pharmacy Shops
      • 5.3.5. Global Talazoparib Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Talazoparib (Price)
      • 5.4.1. Global Talazoparib by: Type (Price)
  • 6. Talazoparib: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
  • 7. Global Talazoparib Sale, by Type, Application, Disease Type, Distribution Channel and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Talazoparib (Value)
      • 7.2.1. Global Talazoparib by: Type (Value)
        • 7.2.1.1. 0.25mg Capsules
        • 7.2.1.2. 1mg Capsules
      • 7.2.2. Global Talazoparib by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Drug Center
        • 7.2.2.3. Clinic
      • 7.2.3. Global Talazoparib by: Disease Type (Value)
        • 7.2.3.1. Treat Prostate Cancer
        • 7.2.3.2. Breast Cancers
        • 7.2.3.3. Endometrial Cancer
        • 7.2.3.4. Uterine Cancer
        • 7.2.3.5. Other
      • 7.2.4. Global Talazoparib by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
        • 7.2.4.3. Specialty Stores
        • 7.2.4.4. Pharmacy Shops
      • 7.2.5. Global Talazoparib Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Talazoparib (Volume)
      • 7.3.1. Global Talazoparib by: Type (Volume)
        • 7.3.1.1. 0.25mg Capsules
        • 7.3.1.2. 1mg Capsules
      • 7.3.2. Global Talazoparib by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Drug Center
        • 7.3.2.3. Clinic
      • 7.3.3. Global Talazoparib by: Disease Type (Volume)
        • 7.3.3.1. Treat Prostate Cancer
        • 7.3.3.2. Breast Cancers
        • 7.3.3.3. Endometrial Cancer
        • 7.3.3.4. Uterine Cancer
        • 7.3.3.5. Other
      • 7.3.4. Global Talazoparib by: Distribution Channel (Volume)
        • 7.3.4.1. Online
        • 7.3.4.2. Offline
        • 7.3.4.3. Specialty Stores
        • 7.3.4.4. Pharmacy Shops
      • 7.3.5. Global Talazoparib Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Talazoparib (Price)
      • 7.4.1. Global Talazoparib by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Talazoparib: by Type(USD Million)
  • Table 2. Talazoparib 0.25mg Capsules , by Region USD Million (2014-2019)
  • Table 3. Talazoparib 1mg Capsules , by Region USD Million (2014-2019)
  • Table 4. Talazoparib: by Application(USD Million)
  • Table 5. Talazoparib Hospital , by Region USD Million (2014-2019)
  • Table 6. Talazoparib Drug Center , by Region USD Million (2014-2019)
  • Table 7. Talazoparib Clinic , by Region USD Million (2014-2019)
  • Table 8. Talazoparib: by Disease Type(USD Million)
  • Table 9. Talazoparib Treat Prostate Cancer , by Region USD Million (2014-2019)
  • Table 10. Talazoparib Breast Cancers , by Region USD Million (2014-2019)
  • Table 11. Talazoparib Endometrial Cancer , by Region USD Million (2014-2019)
  • Table 12. Talazoparib Uterine Cancer , by Region USD Million (2014-2019)
  • Table 13. Talazoparib Other , by Region USD Million (2014-2019)
  • Table 14. Talazoparib: by Distribution Channel(USD Million)
  • Table 15. Talazoparib Online , by Region USD Million (2014-2019)
  • Table 16. Talazoparib Offline , by Region USD Million (2014-2019)
  • Table 17. Talazoparib Specialty Stores , by Region USD Million (2014-2019)
  • Table 18. Talazoparib Pharmacy Shops , by Region USD Million (2014-2019)
  • Table 19. South America Talazoparib, by Country USD Million (2014-2019)
  • Table 20. South America Talazoparib, by Type USD Million (2014-2019)
  • Table 21. South America Talazoparib, by Application USD Million (2014-2019)
  • Table 22. South America Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 23. South America Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 24. Brazil Talazoparib, by Type USD Million (2014-2019)
  • Table 25. Brazil Talazoparib, by Application USD Million (2014-2019)
  • Table 26. Brazil Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 27. Brazil Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 28. Argentina Talazoparib, by Type USD Million (2014-2019)
  • Table 29. Argentina Talazoparib, by Application USD Million (2014-2019)
  • Table 30. Argentina Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 31. Argentina Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 32. Rest of South America Talazoparib, by Type USD Million (2014-2019)
  • Table 33. Rest of South America Talazoparib, by Application USD Million (2014-2019)
  • Table 34. Rest of South America Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 35. Rest of South America Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 36. Asia Pacific Talazoparib, by Country USD Million (2014-2019)
  • Table 37. Asia Pacific Talazoparib, by Type USD Million (2014-2019)
  • Table 38. Asia Pacific Talazoparib, by Application USD Million (2014-2019)
  • Table 39. Asia Pacific Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 40. Asia Pacific Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 41. China Talazoparib, by Type USD Million (2014-2019)
  • Table 42. China Talazoparib, by Application USD Million (2014-2019)
  • Table 43. China Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 44. China Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 45. Japan Talazoparib, by Type USD Million (2014-2019)
  • Table 46. Japan Talazoparib, by Application USD Million (2014-2019)
  • Table 47. Japan Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 48. Japan Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 49. India Talazoparib, by Type USD Million (2014-2019)
  • Table 50. India Talazoparib, by Application USD Million (2014-2019)
  • Table 51. India Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 52. India Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 53. South Korea Talazoparib, by Type USD Million (2014-2019)
  • Table 54. South Korea Talazoparib, by Application USD Million (2014-2019)
  • Table 55. South Korea Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 56. South Korea Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 57. Taiwan Talazoparib, by Type USD Million (2014-2019)
  • Table 58. Taiwan Talazoparib, by Application USD Million (2014-2019)
  • Table 59. Taiwan Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 60. Taiwan Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 61. Australia Talazoparib, by Type USD Million (2014-2019)
  • Table 62. Australia Talazoparib, by Application USD Million (2014-2019)
  • Table 63. Australia Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 64. Australia Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Talazoparib, by Type USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Talazoparib, by Application USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 69. Europe Talazoparib, by Country USD Million (2014-2019)
  • Table 70. Europe Talazoparib, by Type USD Million (2014-2019)
  • Table 71. Europe Talazoparib, by Application USD Million (2014-2019)
  • Table 72. Europe Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 73. Europe Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 74. Germany Talazoparib, by Type USD Million (2014-2019)
  • Table 75. Germany Talazoparib, by Application USD Million (2014-2019)
  • Table 76. Germany Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 77. Germany Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 78. France Talazoparib, by Type USD Million (2014-2019)
  • Table 79. France Talazoparib, by Application USD Million (2014-2019)
  • Table 80. France Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 81. France Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 82. Italy Talazoparib, by Type USD Million (2014-2019)
  • Table 83. Italy Talazoparib, by Application USD Million (2014-2019)
  • Table 84. Italy Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 85. Italy Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 86. United Kingdom Talazoparib, by Type USD Million (2014-2019)
  • Table 87. United Kingdom Talazoparib, by Application USD Million (2014-2019)
  • Table 88. United Kingdom Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 89. United Kingdom Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 90. Netherlands Talazoparib, by Type USD Million (2014-2019)
  • Table 91. Netherlands Talazoparib, by Application USD Million (2014-2019)
  • Table 92. Netherlands Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 93. Netherlands Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 94. Rest of Europe Talazoparib, by Type USD Million (2014-2019)
  • Table 95. Rest of Europe Talazoparib, by Application USD Million (2014-2019)
  • Table 96. Rest of Europe Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 97. Rest of Europe Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 98. MEA Talazoparib, by Country USD Million (2014-2019)
  • Table 99. MEA Talazoparib, by Type USD Million (2014-2019)
  • Table 100. MEA Talazoparib, by Application USD Million (2014-2019)
  • Table 101. MEA Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 102. MEA Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 103. Middle East Talazoparib, by Type USD Million (2014-2019)
  • Table 104. Middle East Talazoparib, by Application USD Million (2014-2019)
  • Table 105. Middle East Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 106. Middle East Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 107. Africa Talazoparib, by Type USD Million (2014-2019)
  • Table 108. Africa Talazoparib, by Application USD Million (2014-2019)
  • Table 109. Africa Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 110. Africa Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 111. North America Talazoparib, by Country USD Million (2014-2019)
  • Table 112. North America Talazoparib, by Type USD Million (2014-2019)
  • Table 113. North America Talazoparib, by Application USD Million (2014-2019)
  • Table 114. North America Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 115. North America Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 116. United States Talazoparib, by Type USD Million (2014-2019)
  • Table 117. United States Talazoparib, by Application USD Million (2014-2019)
  • Table 118. United States Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 119. United States Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 120. Canada Talazoparib, by Type USD Million (2014-2019)
  • Table 121. Canada Talazoparib, by Application USD Million (2014-2019)
  • Table 122. Canada Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 123. Canada Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 124. Mexico Talazoparib, by Type USD Million (2014-2019)
  • Table 125. Mexico Talazoparib, by Application USD Million (2014-2019)
  • Table 126. Mexico Talazoparib, by Disease Type USD Million (2014-2019)
  • Table 127. Mexico Talazoparib, by Distribution Channel USD Million (2014-2019)
  • Table 128. Talazoparib Sales: by Type(K Tons)
  • Table 129. Talazoparib Sales 0.25mg Capsules , by Region K Tons (2014-2019)
  • Table 130. Talazoparib Sales 1mg Capsules , by Region K Tons (2014-2019)
  • Table 131. Talazoparib Sales: by Application(K Tons)
  • Table 132. Talazoparib Sales Hospital , by Region K Tons (2014-2019)
  • Table 133. Talazoparib Sales Drug Center , by Region K Tons (2014-2019)
  • Table 134. Talazoparib Sales Clinic , by Region K Tons (2014-2019)
  • Table 135. Talazoparib Sales: by Disease Type(K Tons)
  • Table 136. Talazoparib Sales Treat Prostate Cancer , by Region K Tons (2014-2019)
  • Table 137. Talazoparib Sales Breast Cancers , by Region K Tons (2014-2019)
  • Table 138. Talazoparib Sales Endometrial Cancer , by Region K Tons (2014-2019)
  • Table 139. Talazoparib Sales Uterine Cancer , by Region K Tons (2014-2019)
  • Table 140. Talazoparib Sales Other , by Region K Tons (2014-2019)
  • Table 141. Talazoparib Sales: by Distribution Channel(K Tons)
  • Table 142. Talazoparib Sales Online , by Region K Tons (2014-2019)
  • Table 143. Talazoparib Sales Offline , by Region K Tons (2014-2019)
  • Table 144. Talazoparib Sales Specialty Stores , by Region K Tons (2014-2019)
  • Table 145. Talazoparib Sales Pharmacy Shops , by Region K Tons (2014-2019)
  • Table 146. South America Talazoparib Sales, by Country K Tons (2014-2019)
  • Table 147. South America Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 148. South America Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 149. South America Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 150. South America Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 151. Brazil Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 152. Brazil Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 153. Brazil Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 154. Brazil Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 155. Argentina Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 156. Argentina Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 157. Argentina Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 158. Argentina Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 159. Rest of South America Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 160. Rest of South America Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 161. Rest of South America Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 162. Rest of South America Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 163. Asia Pacific Talazoparib Sales, by Country K Tons (2014-2019)
  • Table 164. Asia Pacific Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 165. Asia Pacific Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 166. Asia Pacific Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 167. Asia Pacific Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 168. China Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 169. China Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 170. China Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 171. China Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 172. Japan Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 173. Japan Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 174. Japan Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 175. Japan Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 176. India Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 177. India Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 178. India Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 179. India Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 180. South Korea Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 181. South Korea Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 182. South Korea Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 183. South Korea Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 184. Taiwan Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 185. Taiwan Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 186. Taiwan Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 187. Taiwan Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 188. Australia Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 189. Australia Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 190. Australia Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 191. Australia Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 192. Rest of Asia-Pacific Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 193. Rest of Asia-Pacific Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 194. Rest of Asia-Pacific Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 195. Rest of Asia-Pacific Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 196. Europe Talazoparib Sales, by Country K Tons (2014-2019)
  • Table 197. Europe Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 198. Europe Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 199. Europe Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 200. Europe Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 201. Germany Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 202. Germany Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 203. Germany Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 204. Germany Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 205. France Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 206. France Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 207. France Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 208. France Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 209. Italy Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 210. Italy Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 211. Italy Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 212. Italy Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 213. United Kingdom Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 214. United Kingdom Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 215. United Kingdom Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 216. United Kingdom Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 217. Netherlands Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 218. Netherlands Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 219. Netherlands Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 220. Netherlands Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 221. Rest of Europe Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 222. Rest of Europe Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 223. Rest of Europe Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 224. Rest of Europe Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 225. MEA Talazoparib Sales, by Country K Tons (2014-2019)
  • Table 226. MEA Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 227. MEA Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 228. MEA Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 229. MEA Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 230. Middle East Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 231. Middle East Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 232. Middle East Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 233. Middle East Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 234. Africa Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 235. Africa Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 236. Africa Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 237. Africa Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 238. North America Talazoparib Sales, by Country K Tons (2014-2019)
  • Table 239. North America Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 240. North America Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 241. North America Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 242. North America Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 243. United States Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 244. United States Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 245. United States Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 246. United States Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 247. Canada Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 248. Canada Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 249. Canada Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 250. Canada Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 251. Mexico Talazoparib Sales, by Type K Tons (2014-2019)
  • Table 252. Mexico Talazoparib Sales, by Application K Tons (2014-2019)
  • Table 253. Mexico Talazoparib Sales, by Disease Type K Tons (2014-2019)
  • Table 254. Mexico Talazoparib Sales, by Distribution Channel K Tons (2014-2019)
  • Table 255. Talazoparib: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Talazoparib: by Type(USD Million)
  • Table 258. Talazoparib 0.25mg Capsules , by Region USD Million (2020-2025)
  • Table 259. Talazoparib 1mg Capsules , by Region USD Million (2020-2025)
  • Table 260. Talazoparib: by Application(USD Million)
  • Table 261. Talazoparib Hospital , by Region USD Million (2020-2025)
  • Table 262. Talazoparib Drug Center , by Region USD Million (2020-2025)
  • Table 263. Talazoparib Clinic , by Region USD Million (2020-2025)
  • Table 264. Talazoparib: by Disease Type(USD Million)
  • Table 265. Talazoparib Treat Prostate Cancer , by Region USD Million (2020-2025)
  • Table 266. Talazoparib Breast Cancers , by Region USD Million (2020-2025)
  • Table 267. Talazoparib Endometrial Cancer , by Region USD Million (2020-2025)
  • Table 268. Talazoparib Uterine Cancer , by Region USD Million (2020-2025)
  • Table 269. Talazoparib Other , by Region USD Million (2020-2025)
  • Table 270. Talazoparib: by Distribution Channel(USD Million)
  • Table 271. Talazoparib Online , by Region USD Million (2020-2025)
  • Table 272. Talazoparib Offline , by Region USD Million (2020-2025)
  • Table 273. Talazoparib Specialty Stores , by Region USD Million (2020-2025)
  • Table 274. Talazoparib Pharmacy Shops , by Region USD Million (2020-2025)
  • Table 275. South America Talazoparib, by Country USD Million (2020-2025)
  • Table 276. South America Talazoparib, by Type USD Million (2020-2025)
  • Table 277. South America Talazoparib, by Application USD Million (2020-2025)
  • Table 278. South America Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 279. South America Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 280. Brazil Talazoparib, by Type USD Million (2020-2025)
  • Table 281. Brazil Talazoparib, by Application USD Million (2020-2025)
  • Table 282. Brazil Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 283. Brazil Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 284. Argentina Talazoparib, by Type USD Million (2020-2025)
  • Table 285. Argentina Talazoparib, by Application USD Million (2020-2025)
  • Table 286. Argentina Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 287. Argentina Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 288. Rest of South America Talazoparib, by Type USD Million (2020-2025)
  • Table 289. Rest of South America Talazoparib, by Application USD Million (2020-2025)
  • Table 290. Rest of South America Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 291. Rest of South America Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 292. Asia Pacific Talazoparib, by Country USD Million (2020-2025)
  • Table 293. Asia Pacific Talazoparib, by Type USD Million (2020-2025)
  • Table 294. Asia Pacific Talazoparib, by Application USD Million (2020-2025)
  • Table 295. Asia Pacific Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 296. Asia Pacific Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 297. China Talazoparib, by Type USD Million (2020-2025)
  • Table 298. China Talazoparib, by Application USD Million (2020-2025)
  • Table 299. China Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 300. China Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 301. Japan Talazoparib, by Type USD Million (2020-2025)
  • Table 302. Japan Talazoparib, by Application USD Million (2020-2025)
  • Table 303. Japan Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 304. Japan Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 305. India Talazoparib, by Type USD Million (2020-2025)
  • Table 306. India Talazoparib, by Application USD Million (2020-2025)
  • Table 307. India Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 308. India Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 309. South Korea Talazoparib, by Type USD Million (2020-2025)
  • Table 310. South Korea Talazoparib, by Application USD Million (2020-2025)
  • Table 311. South Korea Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 312. South Korea Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 313. Taiwan Talazoparib, by Type USD Million (2020-2025)
  • Table 314. Taiwan Talazoparib, by Application USD Million (2020-2025)
  • Table 315. Taiwan Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 316. Taiwan Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 317. Australia Talazoparib, by Type USD Million (2020-2025)
  • Table 318. Australia Talazoparib, by Application USD Million (2020-2025)
  • Table 319. Australia Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 320. Australia Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 321. Rest of Asia-Pacific Talazoparib, by Type USD Million (2020-2025)
  • Table 322. Rest of Asia-Pacific Talazoparib, by Application USD Million (2020-2025)
  • Table 323. Rest of Asia-Pacific Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 324. Rest of Asia-Pacific Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 325. Europe Talazoparib, by Country USD Million (2020-2025)
  • Table 326. Europe Talazoparib, by Type USD Million (2020-2025)
  • Table 327. Europe Talazoparib, by Application USD Million (2020-2025)
  • Table 328. Europe Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 329. Europe Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 330. Germany Talazoparib, by Type USD Million (2020-2025)
  • Table 331. Germany Talazoparib, by Application USD Million (2020-2025)
  • Table 332. Germany Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 333. Germany Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 334. France Talazoparib, by Type USD Million (2020-2025)
  • Table 335. France Talazoparib, by Application USD Million (2020-2025)
  • Table 336. France Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 337. France Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 338. Italy Talazoparib, by Type USD Million (2020-2025)
  • Table 339. Italy Talazoparib, by Application USD Million (2020-2025)
  • Table 340. Italy Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 341. Italy Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 342. United Kingdom Talazoparib, by Type USD Million (2020-2025)
  • Table 343. United Kingdom Talazoparib, by Application USD Million (2020-2025)
  • Table 344. United Kingdom Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 345. United Kingdom Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 346. Netherlands Talazoparib, by Type USD Million (2020-2025)
  • Table 347. Netherlands Talazoparib, by Application USD Million (2020-2025)
  • Table 348. Netherlands Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 349. Netherlands Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 350. Rest of Europe Talazoparib, by Type USD Million (2020-2025)
  • Table 351. Rest of Europe Talazoparib, by Application USD Million (2020-2025)
  • Table 352. Rest of Europe Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 353. Rest of Europe Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 354. MEA Talazoparib, by Country USD Million (2020-2025)
  • Table 355. MEA Talazoparib, by Type USD Million (2020-2025)
  • Table 356. MEA Talazoparib, by Application USD Million (2020-2025)
  • Table 357. MEA Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 358. MEA Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 359. Middle East Talazoparib, by Type USD Million (2020-2025)
  • Table 360. Middle East Talazoparib, by Application USD Million (2020-2025)
  • Table 361. Middle East Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 362. Middle East Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 363. Africa Talazoparib, by Type USD Million (2020-2025)
  • Table 364. Africa Talazoparib, by Application USD Million (2020-2025)
  • Table 365. Africa Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 366. Africa Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 367. North America Talazoparib, by Country USD Million (2020-2025)
  • Table 368. North America Talazoparib, by Type USD Million (2020-2025)
  • Table 369. North America Talazoparib, by Application USD Million (2020-2025)
  • Table 370. North America Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 371. North America Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 372. United States Talazoparib, by Type USD Million (2020-2025)
  • Table 373. United States Talazoparib, by Application USD Million (2020-2025)
  • Table 374. United States Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 375. United States Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 376. Canada Talazoparib, by Type USD Million (2020-2025)
  • Table 377. Canada Talazoparib, by Application USD Million (2020-2025)
  • Table 378. Canada Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 379. Canada Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 380. Mexico Talazoparib, by Type USD Million (2020-2025)
  • Table 381. Mexico Talazoparib, by Application USD Million (2020-2025)
  • Table 382. Mexico Talazoparib, by Disease Type USD Million (2020-2025)
  • Table 383. Mexico Talazoparib, by Distribution Channel USD Million (2020-2025)
  • Table 384. Talazoparib Sales: by Type(K Tons)
  • Table 385. Talazoparib Sales 0.25mg Capsules , by Region K Tons (2020-2025)
  • Table 386. Talazoparib Sales 1mg Capsules , by Region K Tons (2020-2025)
  • Table 387. Talazoparib Sales: by Application(K Tons)
  • Table 388. Talazoparib Sales Hospital , by Region K Tons (2020-2025)
  • Table 389. Talazoparib Sales Drug Center , by Region K Tons (2020-2025)
  • Table 390. Talazoparib Sales Clinic , by Region K Tons (2020-2025)
  • Table 391. Talazoparib Sales: by Disease Type(K Tons)
  • Table 392. Talazoparib Sales Treat Prostate Cancer , by Region K Tons (2020-2025)
  • Table 393. Talazoparib Sales Breast Cancers , by Region K Tons (2020-2025)
  • Table 394. Talazoparib Sales Endometrial Cancer , by Region K Tons (2020-2025)
  • Table 395. Talazoparib Sales Uterine Cancer , by Region K Tons (2020-2025)
  • Table 396. Talazoparib Sales Other , by Region K Tons (2020-2025)
  • Table 397. Talazoparib Sales: by Distribution Channel(K Tons)
  • Table 398. Talazoparib Sales Online , by Region K Tons (2020-2025)
  • Table 399. Talazoparib Sales Offline , by Region K Tons (2020-2025)
  • Table 400. Talazoparib Sales Specialty Stores , by Region K Tons (2020-2025)
  • Table 401. Talazoparib Sales Pharmacy Shops , by Region K Tons (2020-2025)
  • Table 402. South America Talazoparib Sales, by Country K Tons (2020-2025)
  • Table 403. South America Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 404. South America Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 405. South America Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 406. South America Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 407. Brazil Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 408. Brazil Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 409. Brazil Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 410. Brazil Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 411. Argentina Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 412. Argentina Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 413. Argentina Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 414. Argentina Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 415. Rest of South America Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 416. Rest of South America Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 417. Rest of South America Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 418. Rest of South America Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 419. Asia Pacific Talazoparib Sales, by Country K Tons (2020-2025)
  • Table 420. Asia Pacific Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 421. Asia Pacific Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 422. Asia Pacific Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 423. Asia Pacific Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 424. China Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 425. China Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 426. China Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 427. China Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 428. Japan Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 429. Japan Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 430. Japan Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 431. Japan Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 432. India Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 433. India Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 434. India Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 435. India Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 436. South Korea Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 437. South Korea Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 438. South Korea Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 439. South Korea Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 440. Taiwan Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 441. Taiwan Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 442. Taiwan Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 443. Taiwan Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 444. Australia Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 445. Australia Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 446. Australia Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 447. Australia Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 448. Rest of Asia-Pacific Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 449. Rest of Asia-Pacific Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 450. Rest of Asia-Pacific Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 451. Rest of Asia-Pacific Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 452. Europe Talazoparib Sales, by Country K Tons (2020-2025)
  • Table 453. Europe Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 454. Europe Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 455. Europe Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 456. Europe Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 457. Germany Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 458. Germany Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 459. Germany Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 460. Germany Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 461. France Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 462. France Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 463. France Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 464. France Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 465. Italy Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 466. Italy Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 467. Italy Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 468. Italy Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 469. United Kingdom Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 470. United Kingdom Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 471. United Kingdom Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 472. United Kingdom Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 473. Netherlands Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 474. Netherlands Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 475. Netherlands Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 476. Netherlands Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 477. Rest of Europe Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 478. Rest of Europe Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 479. Rest of Europe Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 480. Rest of Europe Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 481. MEA Talazoparib Sales, by Country K Tons (2020-2025)
  • Table 482. MEA Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 483. MEA Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 484. MEA Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 485. MEA Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 486. Middle East Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 487. Middle East Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 488. Middle East Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 489. Middle East Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 490. Africa Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 491. Africa Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 492. Africa Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 493. Africa Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 494. North America Talazoparib Sales, by Country K Tons (2020-2025)
  • Table 495. North America Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 496. North America Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 497. North America Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 498. North America Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 499. United States Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 500. United States Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 501. United States Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 502. United States Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 503. Canada Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 504. Canada Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 505. Canada Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 506. Canada Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 507. Mexico Talazoparib Sales, by Type K Tons (2020-2025)
  • Table 508. Mexico Talazoparib Sales, by Application K Tons (2020-2025)
  • Table 509. Mexico Talazoparib Sales, by Disease Type K Tons (2020-2025)
  • Table 510. Mexico Talazoparib Sales, by Distribution Channel K Tons (2020-2025)
  • Table 511. Talazoparib: by Type(USD/Units)
  • Table 512. Research Programs/Design for This Report
  • Table 513. Key Data Information from Secondary Sources
  • Table 514. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Talazoparib: by Type USD Million (2014-2019)
  • Figure 5. Global Talazoparib: by Application USD Million (2014-2019)
  • Figure 6. Global Talazoparib: by Disease Type USD Million (2014-2019)
  • Figure 7. Global Talazoparib: by Distribution Channel USD Million (2014-2019)
  • Figure 8. South America Talazoparib Share (%), by Country
  • Figure 9. Asia Pacific Talazoparib Share (%), by Country
  • Figure 10. Europe Talazoparib Share (%), by Country
  • Figure 11. MEA Talazoparib Share (%), by Country
  • Figure 12. North America Talazoparib Share (%), by Country
  • Figure 13. Global Talazoparib: by Type K Tons (2014-2019)
  • Figure 14. Global Talazoparib: by Application K Tons (2014-2019)
  • Figure 15. Global Talazoparib: by Disease Type K Tons (2014-2019)
  • Figure 16. Global Talazoparib: by Distribution Channel K Tons (2014-2019)
  • Figure 17. South America Talazoparib Share (%), by Country
  • Figure 18. Asia Pacific Talazoparib Share (%), by Country
  • Figure 19. Europe Talazoparib Share (%), by Country
  • Figure 20. MEA Talazoparib Share (%), by Country
  • Figure 21. North America Talazoparib Share (%), by Country
  • Figure 22. Global Talazoparib: by Type USD/Units (2014-2019)
  • Figure 23. Global Talazoparib share by Players 2019 (%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2019
  • Figure 27. Global Talazoparib: by Type USD Million (2020-2025)
  • Figure 28. Global Talazoparib: by Application USD Million (2020-2025)
  • Figure 29. Global Talazoparib: by Disease Type USD Million (2020-2025)
  • Figure 30. Global Talazoparib: by Distribution Channel USD Million (2020-2025)
  • Figure 31. South America Talazoparib Share (%), by Country
  • Figure 32. Asia Pacific Talazoparib Share (%), by Country
  • Figure 33. Europe Talazoparib Share (%), by Country
  • Figure 34. MEA Talazoparib Share (%), by Country
  • Figure 35. North America Talazoparib Share (%), by Country
  • Figure 36. Global Talazoparib: by Type K Tons (2020-2025)
  • Figure 37. Global Talazoparib: by Application K Tons (2020-2025)
  • Figure 38. Global Talazoparib: by Disease Type K Tons (2020-2025)
  • Figure 39. Global Talazoparib: by Distribution Channel K Tons (2020-2025)
  • Figure 40. South America Talazoparib Share (%), by Country
  • Figure 41. Asia Pacific Talazoparib Share (%), by Country
  • Figure 42. Europe Talazoparib Share (%), by Country
  • Figure 43. MEA Talazoparib Share (%), by Country
  • Figure 44. North America Talazoparib Share (%), by Country
  • Figure 45. Global Talazoparib: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation